Clinical observation of therapeutic efficacy of insulin sensitizer in treatment of newly-diagnosed type 2 diabetes
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF DIABETES
- Issue:
- 6
- DOI:
- 10.3321/j.issn:1006-6187.2006.06.007
- Key Word:
- 罗格列酮;二甲双胍;糖尿病,2型;Diabetes mellitus,type 2
Abstract： In observing the therapeutic efficacy of insulin sensitizer in treatment of early T2DM,120 T2DM patients were randomly divided into 3 groups: group A received 4 mg rosiglitazone daily;group B received 1.5 g metformin daily;group C received 4 mg rosiglitazone and 1.0 g met-formin every day.Before and after the treatment,fasting glucose,HbA1c,weight,adiponectin,BMI and HOMA-IR were measured or calculated.We found that fasting glucose,HbA1c and HOMA-IR of 3 groups were obviously decreased in comparison with their baseline and adiponectin was significantly increased.In conclusion,insulin sensitizer can obviously decrease the levels of glucose,HbA1c and HOMA-IR,and increase the level of serum adiponectin in T2DM.Insulin sensitizer in combination of metformin is suitable for treatment of T2DM.
- [1]Kruszynska YT,Sinha M,Javorschi S,etc.The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.[J].2002,51(10).
- [2]Gerich J,Stumvoll M.Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes.[J].2001,21(1).
- [3]Boden G,Mozzoli M,Fried SK,etc.Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.[J].2003,52(6).
- [4]Dole JF,ttglobal.net,Freed MI,etc.Rosiglitazone monotherapy is effective in patients with type 2 diabetes.[J].2001,86(1).